|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
9,610,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.72 - $0.72 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Edesa Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases. Co.'s primary product candidates include: EB05, which is a monoclonal antibody therapy for the treatment for Acute Respiratory Distress Syndrome in COVID-19 patients; and EB01, which is a secretory phospholipase 2 (sPLA2) inhibitor for the topical treatment for chronic allergic contact dermatitis, a potentially debilitating condition and occupational illness. Co.'s EB02 drug candidate represents a potential extension of its sPLA2 anti-inflammatory technology. Co.'s product candidate EB06, is a monoclonal antibody candidate.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
5,000 |
5,000 |
5,000 |
41,500 |
Total Buy Value |
$20,000 |
$20,000 |
$20,000 |
$80,667 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
1 |
7 |
Total Shares Sold |
0 |
0 |
0 |
297,474 |
Total Sell Value |
$0 |
$0 |
$0 |
$787,716 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nijhawan Pardeep |
Chief Executive Officer |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,083 |
114,146 |
|
- |
|
Nijhawan Pardeep |
Chief Executive Officer |
|
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,253 |
111,063 |
|
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2024-03-25 |
4 |
B |
$4.00 |
$20,000 |
I/I |
5,000 |
341,702 |
0.01 |
- |
|
Nijhawan Pardeep |
Chief Executive Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,765 |
107,810 |
|
- |
|
Nijhawan Pardeep |
Chief Executive Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,978 |
105,045 |
|
- |
|
Nijhawan Pardeep |
Chief Executive Officer |
|
2024-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,908 |
102,067 |
|
- |
|
Nijhawan Pardeep |
Chief Executive Officer |
|
2023-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
99,300 |
694,112 |
|
- |
|
Brooks Michael J |
President |
|
2023-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
93,200 |
123,680 |
|
- |
|
Lemieux Stephen |
Chief Financial Officer |
|
2023-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,400 |
17,400 |
|
- |
|
Marshall Patrick |
|
|
2023-05-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,254 |
|
- |
|
Chypyha Joan |
|
|
2023-05-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
200 |
|
- |
|
Lumira Capital Investment Management Inc. |
10% Owner |
|
2023-01-10 |
4 |
S |
$2.63 |
$401,368 |
I/I |
(152,345) |
150,275 |
|
- |
|
Lumira Capital Investment Management Inc. |
10% Owner |
|
2023-01-09 |
4 |
S |
$2.66 |
$386,348 |
I/I |
(145,129) |
163,170 |
|
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-11-02 |
4 |
A |
$1.13 |
$513,590 |
I/I |
456,524 |
228,262 |
|
- |
|
Brooks Michael J |
President |
|
2022-11-02 |
4 |
A |
$1.13 |
$4,769 |
D/D |
4,239 |
30,480 |
|
- |
|
Niffenegger Kathi |
Chief Financial Officer |
|
2022-11-02 |
4 |
A |
$1.13 |
$9,999 |
I/I |
8,888 |
10,715 |
|
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-06-30 |
4 |
B |
$1.60 |
$32,078 |
D/D |
20,000 |
594,812 |
0.01 |
- |
|
Brooks Michael J |
President |
|
2022-06-29 |
4 |
B |
$1.49 |
$4,483 |
D/D |
3,000 |
26,241 |
0.01 |
- |
|
Brooks Michael J |
President |
|
2022-06-16 |
4 |
B |
$1.61 |
$4,817 |
D/D |
3,000 |
23,241 |
0.01 |
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-05-27 |
4 |
B |
$1.92 |
$9,599 |
D/D |
5,000 |
574,812 |
0.01 |
- |
|
Brooks Michael J |
President |
|
2022-05-25 |
4 |
B |
$1.74 |
$6,090 |
D/D |
3,500 |
20,241 |
0.01 |
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-05-24 |
4 |
B |
$1.80 |
$3,600 |
D/D |
2,000 |
569,812 |
0.01 |
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-03-31 |
4 |
B |
$2.99 |
$5,972 |
D/D |
2,000 |
567,812 |
0.01 |
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-03-30 |
4 |
B |
$3.05 |
$6,098 |
D/D |
2,000 |
565,812 |
0.01 |
- |
|
Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
|
2022-03-29 |
4 |
B |
$3.02 |
$6,034 |
D/D |
2,000 |
563,812 |
0.01 |
- |
|
95 Records found
|
|
Page 1 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|